World-first phase 1 trial will evaluate efficacy of psilocybin in Short-lasting Unilateral Neuralgiform Headache Attacks (SUNHA) Data expected in early 2022 SUNHA, a rare and debilitating headache condition, is estimated to affect 40,000 patients in US and Europe Oxford, United Kingdom – 14 September 2021 – Beckley Psytech, a private company dedicated to addressing neurological and psychiatric…


Previous articlePsychedelic Bulletin: COMPASS Pathways Acquires IP Portfolio; Wesana to Explore MDMA for TBI With MAPS; Nine Perfect Strangers Draws Attention to Psychedelics
Next articlePT263 – Michelle Janikian – 920: The Magic Mushroom Holiday